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Abstract. Directly observable behavioral effects of the N- 
methyl-D-aspartate (NMDA) receptor antagonist 2-amino- 
5-phosphonovalerate (AP5) (10-1,000mg/kg IP, 0.18- 
5.6 gmol/rat ICV) and ofphencyclidine (PCP) (3.2-56 mg/kg 
IP, 0.032-3.2 rag/rat ICV), ketamine (10-100 mg/kg), am- 
phetamine (1-18mg/kg), apomorphine (0.1 5.6mg/kg), 
chlordiaz~poxide (1-100 mg/kg), and pentobarbital (3.2- 
56 mg/kg) were studied in rats. Pharmacologically specific 
results were obtained rapidly and reliably, using a cumula- 
tive dosing procedure. Cluster analysis grouped the drug 
treatments, on the basis of their similarities in producing 
different behavioral activities, into three main clusters; char- 
acteristically, stimulant drugs (amphetamine, apomorphine) 
produced sniffing and gnawing; PCP-like drugs (PCP, keta- 
mine) produced locomotion, sniffing, swaying and falling; 
sedative drugs (pentobarbital, chlordiazepoxide) produced 
loss of righting. The behavioral effects of ICV administra- 
tion of AP5 were more similar to the effects of PCP-like 
drugs than to the effects of either stimulant or sedative 
drugs, thus supporting the hypothesis that the behavioral 
effects of PCP-like drugs may result from reduced neu- 
rotransmission at excitatory synapses utilizing N M D A  pre- 
ferring receptors. The present procedure is simple, rapid 
and may provide a useful approach in the classification 
of behaviorally active drugs. 
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Recently, we reported that DL-2-amino-5-phosphonovaler- 
ate (AP5), a potent and highly selective N M D A  antagonist 
(Watkins and Evans 1981), produces PCP-like catalepsy, 
discriminative stimulus effects and stereotyped operant re- 
sponding in pigeons (Koek et al. 1986a, b). In addition, 
we observed that the ability of N M D A  antagonists to in- 
duce PCP-like catalepsy is correlated strongly with their 
relative potency as N M D A  antagonists (Mudar et al. 1986). 
Together, these findings suggest that behavioral effects of 
PCP-like drugs in pigeons may be mediated by inhibition 
of neurotransmission at synapses utilizing N M D A  recep- 
tors. The present study sought to examine whether behav- 
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ioral effects of PCP-like drugs in rats may be mediated in 
a similar fashion. 
In rats, PCP induces locomotor activity, stereotypy and 
ataxia. These behavioral effects of PCP have been quantified 
previously by means of rating scales (e.g., Sturgeon et al. 
1979). Quantitative rating scales to evaluate the intensity 
of stereotypy have a number of disadvantages (Fray et al. 
1980; Robbins 1977). Most important, they may confound 
the measurement of stereotypy, which is a description of 
the nature of behavior, with identification of specific re- 
sponses. Further, the use of a quantitative rating scale to 
evaluate PCP-induced behavioral effects in rats appears to 
be complicated by the failure to observe consistently some 
of the behavioral activities included in this scale (e.g., back- 
peddling, "praying"; Greenberg and Segal 1986). A novel 
observational method for measuring behavioral effects of 
dopamine agonists, based on direct observation of the oc- 
currence of a number of different behaviors, has been de- 
scribed (Fray etal. 1980) and has been shown to be useful 
in assessing the behavioral effects of PCP in rats (Iwamoto 
1984). An adaptation of this method, that appears to be 
less complex than a rating-scale approach, was used in the 
present study. 
The first aim of the present study was to investigate 
directly observable effects of PCP in rats using the method 
developed by Fray et al. and using a cumulative-dosing pro- 
cedure that allows the assessment of a dose-response curve 
for each behavior during a single experimental session (e.g., 
Thompson and Boren 1977). In addition, drugs that, to 
varying degrees, may share directly observable behavioral 
effects with PCP were studied to investigate whether the 
method used in the present experiment could discriminate 
reliably between effects induced by PCP-like and non PCP- 
like drugs. Second, the behavioral effects of the NMDA- 
antagonist AP5 were compared to the effects of the PCP-like 
and non-PCP-like drugs tested, to evaluate the hypothesis 
that N M D A  antagonism underlies the behavioral activity 
of PCP in rats. Cluster analysis (e.g., Aldenderfer and Blash- 
field 1984) was used to find subgroups of the drug treat- 
ments that were relatively similar with respect to their di- 
rectly observable behavioral effects and to investigate the 
possible assignment of AP5 to a particular subgroup. The 
generality of the results of the cluster analysis was explored 
across different similarity measures; the replicability was 
evaluated by dividing the data set into two replicates, and 
performing the same method of cluster analysis indepen- 
dently on each half. 
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Materials and methods 
Subjects. Male albino rats of the Sprague-Dawley strain 
(Harlan Industries, Indianapolis, IN) weighing 150-200 g 
at the start of the experiment, were housed individually 
under a 12-h light/dark cycle (lights on at 7 a.m.) and were 
given free access to food and water. In some of the rats, 
a chronic, indwelling guide cannula was implanted under 
anesthesia with the tip directly into the lateral ventricle. 
Apparatus. To assess drug-induced behaviors, four perspex 
cages (25 x 30 x 30 cm high) with a clear front wall and with 
a floor consisting of metal bars (0.3 cm diameter separated 
by 1.0 cm gaps), were used. 
Procedure. During experimental sessions, that were con- 
ducted during the light portion of the light/dark cycle, four 
rats were removed from the home cages, and placed singly 
in an observation cage for a 60-rain habituation period. 
Then, each rat was sequentially observed for 30 s and the 
occurrence of any of the behaviors listed in Table 1 was 
recorded, with the exception of loss of righting and anesthe- 
sia. The behaviors scored were a composite of those from 
previous studies and our preliminary observations; they 
were the behavioral categories described by Fray et al. 
(1980), "fall" was added as described by Iwamoto (1984), 
and loss of righting, anesthesia and Straub tail were also 
noted. A rat was scored for any number of the behaviors 
listed in Table 1, tested for the occurrence of loss of righting 
and anesthesia, injected, and immediately returned to the 
observation cage. Injections were given IP (0.3-1 ml/rat) or 
ICV (5 ~d/rat) at 15-min intervals and behavioral effects 
were assessed 13-15 min after each injection by an observer 
who had no knowledge of the treatment received by the 
rats. Each injected dose (after the first) was calculated such 
that the total amount injected before each test was 1/4-1/2 
log-unit greater than the dose of the previous test. 
First, amphetamine (1-18 mg/kg), PCP (3.2-56 mg/kg), 
and pentobarbital (3.2-56 mg/kg) were tested in a cumula- 
tive-dosing procedure using four rats per drug (groups 1, 
2 and 3, respectively). Two observers (R.C. and M.D.) as- 
sessed independently the occurrence of the different behav- 
iors. The effects of six injections of saline at 15-min intervals 
were assessed by the observers in eight rats (group 4). 
Thereafter, four rats (group 5) were tested with d-am- 
phetamine (1-18 mg/kg), chlordiazepoxide (1-100 mg/kg), 
pentobarbital (3.2-56 mg/kg), PCP (3.2-56 mg/kg), keta- 
mine (10-100 mg/kg), multiple saline injections, and apo- 
morphine (0.1-5.6 mg/kg), in that order; in four other rats 
(group 6), these conditions were tested in the reverse order. 
An additional group of eight rats (group 7) was used to 
study the effects of IP administration of AP5 (10-100 mg/kg 
and 100-1,000 mg/kg, each tested in four rats). PCP (0.032- 
0.56 mg), AP5 (0.18-1.0 ~tmol; i.e., 0.042-0.23 mg) and four 
injections of sterile water at 15-min intervals were tested 
ICV, in that order in four rats (group 8); three rats (group 9) 
received these treatments in the reverse order. Further, mul- 
tiple injections of sterile water and higher ICV doses of 
PCP (0.56-3.2 mg) and of AP5 (1.8-5.6 ~tmol) were tested 
in different groups of rats (groups 10, 11, and 12) that were 
drug-naive (n = 8, 4, and 4, respectively). The pH of the solu- 
tions that were administered ICV ranged from 6 to 7. Be- 
havioral assessments were made by R.C. Test sessions were 
separated by at least 48 h. 
Data analysis. The reliability of the behavioral assessments 
was measured by calculating Cohen's kappa (Leach 1979), 
for each of the behaviors induced by amphetamine, PCP 
and pentobarbital, using the observations by R.C. and by 
M.D. Kappa is directly interpretable as the proportion of 
joint observations in which there is agreement, after chance 
agreement is excluded; kappa attains a value of 1.0 if there 
is perfect agreement between the two observers; a value 
of zero indicates chance agreement and a value of - 1 . 0  
indicates complete disagreement. For each drug and each 
behavior, a 2 x 2 contingency table was constructed with 
the frequencies of the following events as cell entries: 1) 
behavior present according to both observers, 2) behavior 
present according to observer R.C. and absent according 
to observer M.D., 3) behavior absent according to R.C. 
and present according to M.D., and 4) behavior absent ac- 
cording to both observers. Kappa was calculated using the 
formula: 
(nD-Z t, u,)/t. 2 - Z  t, u,) 
where n is the total number of observations, D is the sum 
of the frequencies of the diagonal cells (i.e., cells 1 and 4), 
and ti and ul are the row and column marginal totals con- 
verging on each diagonal cell. For example, in the test of 
the effects of seven dose levels of d-amphetamine on locomo- 
tor activity in four rats (see Fig. 1) there were 15 occasions 
on which both observers marked the occurrence of locomo- 
tor activity, two occasions on which the response was 
marked by R.C. but not by M.D., one occasion on which 
locomotion was marked by M.D. but not by R.C., and ten 
occasions on which locomotion was not marked by both 
observers, resulting in a value for kappa of 0.78. 
To assess the statistical significance of drug-induced 
changes in the occurrence of each of the responses listed 
in Table 1, data were arranged in 2 x 2 contingency tables 
in the following way. For each dose, the number of rats 
showing, as well as those not showing a particular response 
was tabulated. Control values consisted of the number of 
rats showing, as well as those not showing this response 
at the corresponding saline injection (i.e., the effects of the 
first dose of a particular drug were compared with [he effects 
of the first saline injection, etc.). For example, the effects 
of 1.8 mg/kg d-amphetamine on locomotor activity (see 
Fig. 1) were analyzed by constructing a 2 x 2 contingency 
table with the following cell entries: 0 (number of rats that 
did not show locomotion when given drug), 4 (number of 
rats that showed locomotion when given drug), 6 (number 
of rats that did not show locomotion after the second saline 
injection), and 2 (number of rats that showed locomotion 
after the second saline injection). The degree of heterogene- 
ity in each contingency table was calculated by means of 
Kullback's information statistic I (Kullback 1968; Robbins 
1977), analogous to Chi-square, but not constrained by 
small cell frequencies. I is defined as: 
nij lnnlj- ~ nl. lnni.- ~ n.j ln n.j+ N lnN 
where nij is the observed frequency in row i and column 
j, ni. and n.j are marginal totals and N is the grand total. 
2I is distributed as Chi-square with one degree of freedom 
for a 2 × 2 contingency table. The value of 21 in the afore- 
mentioned example is 2 × (0 + 4 In 4 + 6 in 6 + 2 in 2 -  4 In 4 -  
8 In 8 -  6 In 6 -  6 In 6 + 12 in 12)--7.64, a value of Chi-square 
with 1 degree of freedom that is significant at the 1% level. 
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For each drug and each behavioral category, the maxi- 
mum percentage of rats showing the response was deter- 
mined. The statistical significance of differences of this mea- 
sure between groups that received drug treatments in an 
opposite order was assessed by tabulating, for each drug 
and each group, the number of rats showing, as well as 
the remaining number of rats not showing a particular re- 
sponse. The resulting contingency table was analyzed by 
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Fig. 1. Directly observable behavioral effects 
induced, in four rats per drug, by 
cumulative doses of d-amphetamine (upper 
panels), phencyclidine (middle panels) and 
pentobarbital (lower panels). Behavioral 
assessments were made by two independent 
observers who were blind to the treatment 
condition. Effects were marked with an 
asterisk when the assessments of both 
observers were signficiantly different 
(c(=0.05) from the results obtained in a 
different group of eight rats during a test of 
repeated IP injections of saline at 15-rain 
intervals. Drug effects on the activities listed 
in Table 1 that were not statistically 
significant are not shown. Ordinates: 
percentage of rats showing a particular 
activity, as defined in Table 1; abscissae: 
cumulative IP dose administered, in rng/kg 
means of Kullback's I statistic. For example, the maximum 
percentage of rats that showed PCP-induced swaying was 
75 in group 5 (n=4)  and was 100 in group 6 (n=4) .  These 
maxima were observed at a dose of 5.6 mg/kg PCP, in both 
groups. The entries of the contingency table were: 3 (number 
of rats in group 5 that showed swaying), 1 (number of rats 
in group 5 that did not show swaying), 4 (number of rats 
in group 6 that showed swaying), and 0 (number of rats 
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in group 6 that did not show swaying), resulting in a non- 
significant value of Chi-square (i.e., 2 I =  1.53, one degree 
of freedom, p > 0.20). 
Similarities between drugs with respect to the extent to 
which they affected each of the responses were quantified 
by means of Gower's similarity coefficient for quantitative 
variables (Gordon 1981), which can take on values be- 
tween 1 (perfect similarity) and 0 (no similarity). Gower's 
coefficient s~j is defined as: 
Wijk Sijk Wijk" 
k = l  k = l  
In this formula, S~k is the similarity between the ith and 
the j th object as measured by the kth variable, and Wljk 
is 1 or 0 depending on whether or not the comparison is 
valid for the kth variable. For  quantitative variables, Wijk 
is set equal to 0 only when variable k is unknown for one 
or both objects; sij k is defined as 1--1X~k--Xjkl/ek. In the 
context of the present study, W~k was set equal to one in 
all cases, because there were no missing data; X~k--Xjk is 
the difference between the maximum percentage of rats 
showing response k after drug i and the maximum percent- 
age of rats showing response k after drug j ;  Rk is the range 
of maximum percentage values of response k in the sample 
of drug treatments and p is the number of response catego- 
ries (p = 12 in the present study). For  example, the similarity 
between the effects on locomotor  activity of IP and ICV 
administration of PCP (see Table 2) was calculated as 1 -  
(100-86)/(100-13) = 0.84. The overall similarity of the effects 
of IP and ICV administration of PCP was obtained by aver- 
aging across all 12 response categories. A similarity coeffi- 
cient was calculated for every pair of drug treatments. To 
facilitate visual inspection of the similarities between the 
drug treatments, the resulting matrix was used to construct 
a tree-diagram in which drug treatments are sequentially 
joined on the basis of their relative similarities (hierarchical 
agglomerative cluster analysis; Gordon  1981). Drug treat- 
ments are joined at different similarity values as follows: 
at each stage, the most similar pair is amalgamated, then 
the similarity between this new group and the remaining 
groups is calculated as the average similarity between each 
of the members of the new group and the remaining groups 
(average linkage method). The most similar pair in the re- 
sulting matrix is joined and a new matrix is calculated. 
The process stops when all drug treatment groups are linked 
together. 
To study the generality across different similarity mea- 
sures, the cluster analysis was performed also using the sim- 
ple matching coefficient and Jaccard's coefficient (Gordon 
1981). Both coefficients are used as measures of the degree 
of similarity between cases described by binary variables. 
In the context of the present study, the matching coefficient 
between two drug treatments was defined as the number 
of behaviors that were significantly affected by both drugs, 
divided by the total number of behavioral activities (i.e., 
12); Jaccard's coefficient was defined as the number of be- 
haviors that were significantly affected by both drugs, di- 
vided by the number of behaviors significantly affected by 
either drug. Thus, the latter coefficient, unlike the former, 
excludes negative matches between drugs (i.e., instances in 
which both drugs fail to significantly affect a particular be- 
havior). 
To investigate the replicability of the cluster solution, 
Table 1. Definition of behavioral activities recorded observationally 
during 30-s evaluation periods (adapted from Fray et al. 1980; Iwa- 
moto 1984) 
Activity Description 









Loss of righting 
Anesthesia 
Straub tail 
Locomotion with all four legs moving 
Rearing, with the head at least 12 cm above the 
cage floor 
Sniffing for at least 3 s 
Licking cage for at least 3 s 
Gnawing on cage for at least 3 s 
Grooming, with fore paws or hind paws, for at 
least 3 s 
Locomotion with nose within 2 cm of the floor 
Swaying movements of the head (and upper tor- 
so) from side to side for at least one complete 
cycle (i.e., left-right-left) 
Falling from a rearing or standing position back- 
wards or to the side 
Failure to right from a supine position within 
15s 
Loss of righting in combination with absence of 
both vocalization and limb withdrawal upon 
pinching the toes of the hind paws 
Tail in an erect position 
the cluster analysis was performed independently on data 
obtained in group 5, group 8 and in half of the rats of 
group 11 and of group 12 on the one hand, and in group 6, 
group 9 and in the remaining rats of group 11 and of group 
12 on the other hand, using Gower's similarity coefficient. 
Because groups 5 and 8 received the drug treatments in 
an order that was opposite to that used in groups 6 and 
9, this analysis provides information about the replicability 
of the cluster solution across different treatment orders. 
Drugs. The compounds used were d-amphetamine sulfate, 
apomorphine hydrochloride (Sigma Chemical Co., St. 
Louis, MO), phencyclidine and ketamine hydrochloride 
(Warner-Lambert/Parke-Davis and Co., Ann Arbor, MI), 
DL-2-amino-5-phosphonovalerate hydrochloride (AP5) (Dr. 
P. Ornstein), pentobarbital sodium (Gaines Chemical 
Works, New York, NY) and chlordiazepoxide hydrochlo- 
ride (Hoffmann-La Roche, Nutley, NJ). AP5 was dissolved 
in a minimum quantity of 1 N NaOH,  to which sterile water 
was added. All other drugs were dissolved in sterile water. 
Doses of drugs are expressed in the forms described above. 
Results 
Amphetamine, PCP, and pentobarbital produced dose-de- 
pendent changes among the various response categories 
(Fig. 1). Behaviors that were not significantly affected are 
not shown. Each drug produced a different profile of behav- 
ioral activity. Gnawing was induced exclusively by amphet- 
amine; swaying, falling and Straub tail appeared to be char- 
acteristic for PCP, and full anesthesia was produced only 
by pentobarbital. In general, there was close agreement be- 
tween the assessments of the behaviors that are shown in 
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Table 2. Behavioral effects induced by different drug treatments in rats 
Loco Rear Sniff Lick Gnaw Groom Head Sway Fall Loss of Anesth. Straub 
down righting tail 
PCP % 100 25 100 0 0 0 25 88 88 25 0 75 
D 3.2 3.2 5.6 - - 5.6 5.6 10 32 - 56 
PCP ICV % 86 0 86 0 0 43 57 86 86 0 0 43 
D 100 100 - - 56 100 180 180 - - 3200 
Ketamine % 88 25 100 0 13 0 0 38 75 100 0 0 
D 18 10 18 - 32 - - 32 56 100 
AP5 ICV % 71 29 71 0 0 57 14 43 71 100 0 0 
D 0.32 0.18 0.32 - - 0.32 0.32 0.32 0.56 5.6 - - 
Amphetamine % 100 100 100 0 88 0 25 13 0 0 0 0 
D 3.2 3.2 1.8 - 10 - 10 18 - - - 
Apomorphine % 38 38 100 75 88 13 0 0 0 0 0 0 
D 0.32 0.32 1.0 3.2 3.2 0.1 . . . .  
Chlordiazepoxide % 25 13 25 0 0 0 0 0 0 63 0 0 
D 3.2 1.0 3.2 . . . .  100 
Pentobarbital  % 13 0 13 0 0 0 13 0 0 100 88 0 
D 5.6 - 5.6 - - 5.6 - 56 56 - 
Behaviors .are defined as in Table 1. Drugs are administered IP, unless stated otherwise, using a cumulative dosing procedure. The 
% sign indicates the maximum percentage of rats (n = 8 in tests of IP administered drugs and n-= 7 when drugs are tested ICV) showing 
a particular behavior;  when underlined, this percentage is significantly different from control values (c~=0.05). D indicates the lowest 
dose at which the maximum effect is attained. Doses of AP5 are expressed in gmol/rat  and doses of PCP, when administered ICV, 
are expressed in gg/rat. All other doses are expressed in mg/kg 
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Fig. 2. Behavioral activities 
induced by ICV administration 
of cumulative doses of AP5. 
Ordinates: percentage of rats 
showing a particular activity; 
abscissae: cumulative ICV dose 
administered, in gmol/rat. The 
injection volume was 5 gl/ 
injection. Seven rats were tested 
with 0.18-1 gmol AP5, four rats 
were tested with 1.8-5.6 gmol 
and seven rats were tested with 
four ICV injections of sterile 
water, at 15-min intervals. 
Asterisks indicate significant 
differences at the 5% level 
between results obtained after 
administration of AP5 and of 
sterile water 
Fig. 1 b y  the  two  i n d e p e n d e n t  obse rve r s :  the  m e a n  va lue  
of  C o h e n ' s  k a p p a  was  0.9 ( r ange  0.6 1.0). T h e  va lue  of  k a p -  
p a  was  1.0 for  the  b e h a v i o r s  n o t  s h o w n  in Fig. 1 ; t he  obse rv -  
ers a g r e e d  c o m p l e t e l y  o n  the  a b s e n c e  of  these  behav io r s .  
N o t e  t h a t  n o n e  of  the  r e sponses  l is ted in T a b l e  1 o c c u r r e d  
at  the  b e g i n n i n g  of  a c u m u l a t i v e  d o s i n g  sess ion  a n d  t h a t  
the i r  f r equency  of  o c c u r r e n c e  d u r i n g  mul t ip l e  sa l ine  sess ions  
was  a lways  lower  t h a n  25%.  
T a b l e  2 s u m m a r i z e s  the  resu l t s  o b t a i n e d  d u r i n g  a s e c o n d  
series of  d r u g  tests,  in  different  rats .  Because  the  resu l t s  
of  the  s u b g r o u p s  t h a t  rece ived  d r u g  t r e a t m e n t s  in  di f ferent  
o rde r s  were  n o t  s igni f icant ly  di f ferent  (P  > 0.05), these  resul t s  
were  c o m b i n e d .  Sa l ine  tes t  results ,  o b t a i n e d  d u r i n g  tests  
t h a t  were  i n t e r spe r s ed  a m o n g  d r u g  tes t  sessions,  were  s imi-  
la r  to  the  resu l t s  of  mu l t i p l e  sa l ine  in jec t ions  o b t a i n e d  dur -  
ing  the  first p a r t  of  the  p r e sen t  s tudy.  Thus ,  the  p rev ious ly  
o b t a i n e d  sa l ine  d a t a  se rved  as i n d e p e n d e n t  c o n t r o l  va lues  
in  the  a s s e s s m e n t  of  the  s ta t i s t ica l  s igni f icance  of  the  d r u g  
effects o b s e r v e d  af ter  IP  a d m i n i s t r a t i o n .  T h e  resul t s  of  the  
r e p e a t e d  I C V  in jec t ions  of  steri le w a t e r  in  the  d r u g - t r e a t e d  
ra t s  were  s imi la r  to  the  d a t a  o b t a i n e d  in the  r a t s  t h a t  were  
t es ted  w i th  r e p e a t e d  I C V  in jec t ions  of  s ter i le  w a t e r  only.  
T h e  d a t a  o b t a i n e d  in th is  l a t t e r  g r o u p  of  rats ,  s h o w n  in  
Fig. 2, s e rved  as i n d e p e n d e n t  c o n t r o l  va lues  in  t e s t ing  the  
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Table 3. Values of Gower's similarity coefficient for quantitative 
variables that indicate the degree of similarity between the different 
drug treatments, based on profiles of drug-induced directly observ- 
able behavioral effects 
2 3 4 5 6 7 8 
1 PCP 
2 PCP ICV 
3 Ketamine 






0.78 0.73 0.64 0 .60  0.44 0 .53  0.40 
0.62 0 .68  0 .50  0 .40  0 .46  0.36 
0.83 0 .64  0 .58  0 .71  0.60 
0.52 0 .49  0.66 0.59 
0.74 0 .60  0.47 
0.66 0.49 
0.83 
statistical significance of the effects observed after ICV ad- 
ministration of PCP and of AP5. 
AP5 significantly induced locomotion, sniffing, swaying, 
falling and loss of righting (Fig. 2, Table 2). The maximum 
drug effect on locomotion, sniffing, and swaying occurred 
at the same dose; falling was induced at a higher dose and 
loss of righting at the highest doses tested. The directly 
observable behavioral effects induced by ICV administra- 
tion of AP5 appeared to be most similar to the effects of 
ketamine; the similarity between these drug treatments was 
larger (Gower's coefficient = 0.83, matching coefficient = 1.0, 
Jaccard's coefficient = 1.0) than the similarity values between 
the effects of AP5 and any of the other drug treatments. 
However, the rats that were tested with 1.8-5.6 ~tmol of 
AP5 died as a result of complications associated with pro- 
longed respiratory depression between 2 and 4 days after 
the test session. Convulsions were not observed to occur. 
Systemic administration of AP5 did not produce any of 
the behavioral activities listed in Table 1, when tested in 
doses from 10 to 1,000 mg/kg (results not shown). 
PCP induced, at increasing doses, locomotion, sniffing, 
swaying, falling and Straub tail, in that sequence both after 
IP and ICV administration (Table 2). Tremors were ob- 
served at the highest dose tested. These effects were similar 
after both routes of administration and were observed at 
ICV doses of PCP that were about 6-11 times lower than 
IP doses of PCP. 
The matrix displayed in Table 3 was calculated from 
the data in Table 2 and was used to construct a tree-dia- 
gram that described the similarities between the behavioral 
profiles of the different drug treatments. The highest similar- 
ity value in the table is 0.83, both for ICV administration 
of AP5 and ketamine and for pentobarbital and chlordiaze- 
poxide. Hence, AP5 was linked to ketamine and pentobarbi- 
tal was linked to chlordiazepoxide at this similarity level. 
The similarity of the amalgamation of AP5 and ketamine 
to the other drug treatments was calculated by averaging 
the similarities of the other treatments to AP5 and to keta- 
mine (i.e., an average linkage method was used). For  exam- 
ple, the similarity of PCP to the new group was calculated 
as (0.73 + 0.64)/2 = 0.69. 
Figure 3 shows the tree-diagram that described the re- 
sults of the cluster analysis. The different drug treatments 
appeared to be grouped into three main clusters, i.e., stimu- 
lant drugs (amphetamine, apomorphine), PCP-like drugs 
(PCP, ketamine, AP5) and sedative drugs (pentobarbital, 
chlordiazepoxide). AP5 was grouped in the cluster of PCP- 
like drugs on the basis of its directly observable behavioral 
effects when administered ICV. The results obtained when 
the matching coefficient and Jaccard's coefficient were used 
as measures of similarity between drug treatments were al- 
most identical to the aformentioned results obtained with 
Gower's coefficient. The tree-diagrams that were obtained 
when the data set was divided into two and each half ana- 
lyzed independently were also very similar to the tree-dia- 
gram depicted in Fig. 3. These tree-diagrams are therefore 
not shown. 
I I I I 




A P 5 ,  I.C.V. 
KETAMINE 
PHENCYCLIDINE 
PHENCYCLIDINE , I.C.V. 
PENTOBARBITAL 
CHLORDIAZEPOXIDE 
Fig. 3. Tree-diagram describing the similarities 
between the profiles of directly observable 
behavioral activity of the drug treatments listed on 
the right-hand side of the figure. Similarity, shown 
on the abscissa, was measured using Gower's 
coefficient for quantitative variables. The tree- 
diagram was constructed using hierarchical 
agglomerative cluster analysis. The drug treatments 
appeared to cluster into three main groups, i.e., 
stimulant drugs (amphetamine, apomorphine), 
phencyclidine-like drugs (phencyclidine, ketamine, 
AP5) and sedative drugs (pentobarbital, 
chlordiazepoxide). Note that AP5 was grouped in 
the cluster of PCP-like drugs 
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Discussion 
The first aim of the present study was to characterize the 
directly observable effects of PCP and of drugs that may 
produce some, but not all, of these effects, using an adapta- 
tion of observational methods (Fray et al. 1980) and a cu- 
mulative dosing procedure. The results indicate that the 
drug-induced changes in behavior can be observed reliably, 
as evidenced by a close agreement between independent 
observers, blind to the drug treatment. Further, each of 
the drugs appeared to produce a specific pattern of behav- 
ioral changes. Amphetamine induced locomotion, rearing, 
sniffing and gnawing, both in the first and in the second 
experiment. PCP produced locomotion, sniffing, swaying 
and falling in both experiments. Pentobarbital induced ex- 
clusively loss of righting and anesthesia, in both experi- 
ments. These results were not significantly different in rats 
that received the drug treatments in different orders. 
In general, the results obtained with amphetamine in 
the cumulative dosing procedure are in agreement with the 
amphetamine-induced increase of locomotion, rearing and 
sniffing reported by Fray et al. (1980) in a single dosing 
procedure. However, amphetamine was observed to pro- 
duce gnawing in the present experiment, but not in the 
study by Fray et al. Other authors (e.g., Schiorring 1971) 
have reported increases in gnawing by amphetamine, lead- 
ing Fray et al. to conclude that amphetamine-induced 
gnawing may depend to a large extent on environmental 
factors. The results obtained with PCP in the present experi- 
ment are in complete agreement with the PCP-induced in- 
creases of locomotion, sniffing, swaying and falling, but not 
of other behaviors, reported by Iwamoto (1984) in a single 
dosing procedure. PCP was found to be about 6-11 times 
more potent in inducing directly observable behavioral ef- 
fects after ICV administration as compared to IP adminis- 
tration. This potency ratio is similar to the recently reported 
ICV - IP potency ratio for discriminative stimulus effects 
of PCP in rats (i.e., about 7, studied in a single dosing proce- 
dure; Slifer and Balster 1985). In the present study, PCP 
did not induce full anesthesia, in agreement with observa- 
tions by Chen (1956) that PCP does induce anesthesia in 
some species (e.g., rhesus monkey, dog), but not in other 
species (e.g., rats, mice). Pentobarbital was tested in the pres- 
ent study up to anesthetic doses. Although barbiturates and 
benzodiazepines are known to produce ataxia, these effects 
were evidenced only by a complete loss of the righting reflex 
under the conditions of the present study. The results of 
the first part of the present study suggest that the adaptation 
of the method of Fray et al. produces pharmacologically 
specific results, that can be obtained reliably and rapidly 
using a cumulative-dosing procedure. 
The second part of this study was aimed at evaluating 
further the hypothesis that behavioral effects of PCP-like 
drugs may result from reduced neurotransmission at excit- 
atory synapses utilizing N M D A  preferring receptors. The 
drug treatments tested appeared to be grouped, on the basis 
of their similarities in producing different behavioral activi- 
ties, into three main clusters, i.e., stimulant drugs (amphet- 
amine, apomorphine), PCP-like drugs (PCP, ketamine, AP5) 
and sedative drugs (pentobarbital, chlordiazepoxide), irre- 
spective of similarity measure. The cluster solution appeared 
to have a high degree of replicability, as evidenced by the 
close agreement between the cluster solutions that were ob- 
tained when the data set was divided into two and the 
cluster analysis was performed independently on both 
halves. The stimulant drugs characteristically produced 
sniffing and gnawing; the PCP-like drugs produced locomo- 
tion, sniffing, swaying and falling; the sedative drugs pro- 
duced loss of righting. The behavioral effects produced by 
the N M D A  antagonist AP5 when administered ICV were 
more similar to the behavioral effects of PCP-like drugs 
than to the effects of the stimulant and the sedative drugs, 
supporting the aforementioned hypothesis about the mech- 
anism underlying the behavioral effects of PCP. These re- 
sults appear to be in agreement with the enhanced locomo- 
tion and sniffing produced by AP5 (1 ~g) when administered 
in the pars compacta of the substantia nigra and the seda- 
tion induced by administration of AP5 in the pars reticulata 
of the substantia nigra (Dawbarn and Pycock 1981). The 
results obtained with intracerebral injection of AP5 are sug- 
gestive of a possible anatomical dissociation between the 
stimulating and sedative effects of PCP-like drugs. 
Bennett et al. (1985, 1986) have reported that the 
N M D A  antagonist 2-amino-7-phosphonoheptanoic acid 
(AP7), when administered IP in rats, produced anticonflict 
activity, generalized to diazepam discriminative stimuli, and 
produced rotorod deficits at 100 and 173 mg/kg. The au- 
thors suggest that this diazepam-like profile of action of 
AP7 may be based on muscle relaxant activity of AP7 that 
is not mediated by benzodiazepine receptors since the rotor- 
od deficit could not be antagonized by the benzodiazepine 
antagonist CGS 8216. In the present study no evidence was 
obtained for behavioral activity of systemically admin- 
istered AP5, when tested up to a dose of 1,000 mg/kg. The 
procedure used in the present study was sensitive to the 
effects of chlordiazepoxide. However, weak muscle relaxant 
effects of systemic administration of AP5 may not have been 
observed in the present study because muscle relaxation 
can be observed only if it is sufficiently severe to result 
in loss of righting, in the procedure used herein. That 
N M D A  antagonists may produce anti-confict activity is 
not inconsistent with a possible PCP-like profile of action 
of these compounds, as PCP has been reported to possess 
anti-conflict activity (e.g., Cook and Davidson 1973). Fur- 
ther, ICV administration of AP7 shares discriminative stim- 
ulus properties with PCP in rats (Willetts et al. 1986). 
A cluster can be described as a group of similar, but 
not necessarily identical objects. In the present study, differ- 
ent behavioral effects could be observed within clusters of 
similar drugs. Amphetamine induced locomotion and did 
not induce licking, unlike apomorphine; chlordiazepoxide 
did not induce anesthesia, unlike pentobarbital; PCP did 
not induce loss of righting in all subjects, unlike ketamine. 
Although the effects of ICV administration of AP5 appeared 
to be most similar to the effects of ketamine, there was 
an important difference between these drugs in that AP5 
was found to produce loss of righting only when admin- 
istered in toxic doses. The toxicity did not appear to be 
an acute effect of AP5 as three out of the four rats tested 
died 2 or more days after drug administration. In pigeons, 
ICV administration of AP5 produced PCP-like catalepsy 
at non-lethal doses (i.e., 1 gmol; Koek et al. 1986a). Further, 
in pigeons AP5 produced catalepsy also when administered 
systemically, at a dose (i.e., 320 mg/kg; Koek et al. 1986b) 
that was about 700 times higher than the ICV dose. In the 
present study, AP5 produced an increase in locomotor ac- 
tivity when given ICV in a dose of 0.32 gmol/rat (i.e., 
0.075 mg), but failed to do so upon systemic administration 
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of a dose that  was about  3,000 times higher. Together, these 
results suggests that  the b lood-bra in  barr ier  is more perme- 
able to AP5 in pigeons than in rats. In  addit ion,  metabol ic  
differences may also underly the differential effects of AP5 
in pigeons and in rats. The relatively higher b lood-bra in  
barr ier  to AP5 in rats may be responsible for the delayed 
toxicity of ICV adminis t ra t ion of AP5, as the higher b lood-  
brain barrier  may prolong the time that  the drug concentra-  
t ion in the bra in  remains high, upon which toxicity may 
occur. 
In summary,  the directly observable behavioral  effects 
of the N M D A  antagonis t  AP5 in rats appeared  to be more 
similar to the effects of PCP-like drugs (PCP, ketamine) 
than to the effects of either s t imulant  drugs (amphetamine,  
apomorphine)  or  sedative drugs (chlordiazepoxide, pento-  
barbital),  thus support ing the hypothesis  that  N M D A  an- 
tagonism may mediate the effects of PCP, and suggesting 
the usefulness of the present procedure  in classifying PCP- 
like, s t imulant-  and sedative drugs. Whether  the simple and 
rapid  procedure used in the present study may have a more 
general applicabil i ty in the classification of behavioral ly ac- 
tive drugs awaits further s tudy in which other major  drug 
classes (e.g., opiates, neuroleptics, anticholinergics) are in- 
cluded. 
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